Sulzer Suit Seeks Damages From Medtronic On Bone Dowel Regulatory Stance
This article was originally published in The Gray Sheet
Executive Summary
Medtronic misrepresented Sulzer Medica's position on possible FDA regulation of bone dowel implants of human origin in "inflammatory" letters to spine surgeons, a suit filed Sept. 8 in Minneapolis federal court alleges.
You may also be interested in...
Tissue, Cell-Based Product Reg Needs Some Clarification - FDA Staffers
FDA's proposed rule to establish regulations on human cellular or tissue-based medical equipment requires further clarification, agency staffers acknowledged.
Tissue, Cell-Based Product Reg Needs Some Clarification - FDA Staffers
FDA's proposed rule to establish regulations on human cellular or tissue-based medical equipment requires further clarification, agency staffers acknowledged.
Spine-Tech's Comparison Of BAK To Sofamor Inter Fix "Misleading" - FDA
Sulzer Spine-Tech's claim that the BAK Interbody Fusion System has been implanted in over 40,000 patients whereas Medtronic Sofamor Danek's Inter Fix device has been used in roughly 200 patients is "misleading" and misrepresents data used to support FDA approval of the devices, FDA says in a Feb. 17 warning letter.